Solanezumab Fails to Slow Cognitive Decline in Preclinical Alzheimer Disease Trial

Solanezumab did not slow the progression of cognitive decline in preclinical Alzheimer disease, according to results from the A4 Study.

Related Keywords

John Sims , Eli Lilly , Anti Amyloid Treatment , Asymptomatic Alzheimer , Preclinical Alzheimer Cognitive Composite , Clinical Dementia Rating Global ,